Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. - Wikidata - wikimedia - TriplyDB

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

http://www.wikidata.org/entity/Q34162534

about

The clinical management of BRCA1 and BRCA2 mutation carriers Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers BRCA2 mutation carriers, reproductive factors and breast cancer risk The Consequences of a BRCA Mutation in Women Challenging and complex decisions in the management of the BRCA mutation carrier Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data.Genomic imprinting and environment in hereditary paraganglioma.Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia.Towards evidence-based management of inherited breast and breast-ovarian cancer.The prevention of hereditary breast and ovarian cancer: a personal view Two decades after BRCA: setting paradigms in personalized cancer care and prevention Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.Hormonal contraception and risk of cancer.Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.Tubal ligation and the risk of ovarian cancer: review and meta-analysis.Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer Clinical management of hereditary breast cancer syndromes.Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.An overview of hereditary breast and ovarian cancer syndrome.Clinical management of BRCA1 and BRCA2 mutation carriers.Modifiers of risk of hereditary breast cancer.Risk of cancer development in relation to oral contraception.Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?Update on hereditary breast cancer.Hormonal contraception in adolescents: special considerations.Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.Cancer risks among BRCA1 and BRCA2 mutation carriers.Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers

P2860

Q22252596-643FBF42-C6E8-4176-BDD4-34B69A865594 Q24654487-D86F2715-EEC7-492D-89B3-43D4CD160A82 Q24803237-CBDEDE9C-C03E-468D-B891-0AE2A371EB24 Q26777891-2CA86FEA-E70D-4DF1-840C-88ABC3E81C34 Q27026559-92B773EB-78E1-418E-98A7-6F9AD59E0B54 Q30423597-BAA314C1-EADC-44F5-A786-DF477DE1AE8E Q30433319-E12747E4-3EE9-449F-98EE-63E33115FD66 Q30983330-5EA1977D-5C62-4DD3-80F4-7C066AB40254 Q33431893-B80B2901-E7E9-4BD4-8900-9A9FA6745738 Q33582300-30DB2C3D-7F7E-4B86-9949-A32F4C643FAA Q33722557-1C33C893-AC6F-4197-940E-FF7FC34E5124 Q33732247-C956A15E-BF9E-41FA-B304-F1D1E2D29A3B Q33732274-1A2988B4-A4C3-458E-96DC-3E237CD05EBB Q33820594-29501CB9-7173-42DB-A439-4A7B3A11E535 Q33845209-5208E6BA-1560-4F50-9199-9FFEFB9A34DC Q34077422-E6B97EE1-6220-4E84-A1D0-D14238802610 Q34120493-CC119010-5A49-4464-A5DF-035A5EE2B86A Q34126089-89DFDEE6-D21E-45C0-AD4E-D9260FB001F7 Q34126227-E753277C-240B-4291-A7F2-C1A6A723CA37 Q34152848-E90F94B3-CE74-492C-B1BA-2F9A06D740AA Q34167563-352977C3-960F-4462-A4AB-DA5BC25FF065 Q34216239-C275AFB4-F361-40D2-9FC1-F8C4B332E861 Q34305000-EF36927A-14E9-4299-BC88-ACDF098AB310 Q34568554-4A4E8F53-8198-49FB-B523-F5728BFAFD92 Q34568559-24B892B9-195B-4EC9-BDA6-829DDE77F579 Q34575924-ADB24A17-A6A6-48E6-BE6D-90F0622E3ADB Q34910918-F18E8E53-669B-466E-AB5D-5C56786F157D Q35687632-A440BA93-FA54-48EF-82E5-1009315804B8 Q35894534-37BA4E78-E2C2-4B47-AA0A-8B8CB823CFBD Q35906333-1171F0CB-1FB0-4678-A22E-EA16CA54E81F Q35907001-52829755-2769-4351-8BDA-AC7FCBC3459E Q35925255-F51ABA75-F354-4359-8594-69B59589DBF9 Q36254990-B1E9688E-843B-49E6-891F-E0B37C2C4573 Q36389876-D8FA0395-FBE1-4292-B03B-E3C28A89E0C4 Q36403670-136932F5-F7D9-4D89-8081-3204E4F7F28E Q36472233-B7F36D8E-8861-4CC7-88E9-844C7957B1BC Q36610578-935FA2D2-5FB4-4F5F-AF92-967F53B37C15 Q36619933-E3C0C026-6682-4442-90AA-27FE819CD1CF Q36696565-03063CFE-C939-443C-8068-73BE84D77775 Q36706659-5EF492A8-EA2A-4F80-8314-8069B8D848E2

P2860

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

http://www.wikidata.org/entity/Q34162534

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@ast

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@en

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@nl

type

label

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@ast

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@en

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@nl

prefLabel

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@ast

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@en

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@nl

P1433

Q34162534-2013D60A-3B21-48D8-89CD-E89A81F4DDB7

P1476

Q34162534-27AC6ACF-B681-472F-9E57-F40FA2D34A8E

P2093

Q34162534-08A4FAA4-D8F3-4189-8DAD-55A828483768

Q34162534-08AD224F-4993-4CD5-AE98-2B401C6AF5F2

Q34162534-2878890F-F3A8-4F46-8D83-360DF8C95974

Q34162534-2F27579E-C08B-48F5-9243-39868D968AEC

Q34162534-4414BE2A-EEB1-4307-8679-DDB8E44C9424

Q34162534-54E2F213-7EB4-4D9C-B53D-E6FEF6502657

Q34162534-5EE8A5F0-477B-4DE0-AF28-C52C619C644F

Q34162534-6C27757C-EA3D-44CD-A536-02A1761AE8AF

Q34162534-790B8777-B285-412D-A35D-EA7DDB20AB35

Q34162534-816B1CDF-E51B-4021-BA0F-A8FCB4945FE3

P304

Q34162534-0F5E7101-8EB6-4A07-94E1-19224EF76B6F

P31

Q34162534-A7925847-A97B-44A7-9DD2-A06C4FB25DF3

P356

Q34162534-B2D5AF0E-23E6-43FF-8D14-4E5D85783946

P407

Q34162534-257D2127-F8F9-441A-91C7-F11EFD312C1B

P433

Q34162534-29B103F6-CC17-4F24-ABF6-8E6942ACCDC8

P478

Q34162534-813CBFF9-14E7-484F-BA8D-3C83DE9D49DD

P50

Q34162534-03B038EA-CFAA-47CF-8347-B0615315AAED

Q34162534-15386517-D816-492F-BFC0-3AF1B16B999B

Q34162534-189E4411-6316-444B-ACD8-40878B9D17B0

Q34162534-4253CD77-F5B4-4192-BFDF-343DC9330DEF

Q34162534-5985AEBB-1AF6-4B75-A37D-16814F3AA5FA

Q34162534-5A7C5BBD-0BF5-4ADD-9F85-6B7E758FC326

Q34162534-654E7FB4-B49A-47CB-83BC-9D74D4473852

Q34162534-691BF843-8BE3-494B-A575-05BCD1251BD6

Q34162534-92E086AF-1BC3-4813-8B00-60A04C0F77D3

Q34162534-B019C11A-B084-4214-974D-8BEBC270CB78

P577

Q34162534-FAFD4F25-ADB3-4353-921B-0ABC251FDF4D

P5875

Q34162534-FC920B06-3AF3-4250-A906-6D6B4AE1F085

P698

Q34162534-6C599036-9803-490B-A450-D1241CD6B237

P356

P1433

Journal of the National Cancer Institute

P1476

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

@en

P2093

Barbara Pasini

http://www.w3.org/2001/XMLSchema#string

Barbara Weber

http://www.w3.org/2001/XMLSchema#string

Charmaine Kim-Sing

http://www.w3.org/2001/XMLSchema#string

Diane Provencher

http://www.w3.org/2001/XMLSchema#string

Eitan Friedman

http://www.w3.org/2001/XMLSchema#string

Ellen Warner

http://www.w3.org/2001/XMLSchema#string

Hakan Olsson

http://www.w3.org/2001/XMLSchema#string

Helena Jernstrom

http://www.w3.org/2001/XMLSchema#string

Henry T Lynch

http://www.w3.org/2001/XMLSchema#string

Howard M Saal

http://www.w3.org/2001/XMLSchema#string

P304

1773-1779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/94.23.1773

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Pierre Dubé

William D Foulkes

Marion Gauthier-Villars

Ketil R. Heimdal

Steven A. Narod

Fergus J. Couch

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273041377

http://www.w3.org/2001/XMLSchema#string

P698

12464649

http://www.w3.org/2001/XMLSchema#string